Adjusted EPS fell from $1.88 to $1.37, missing the consensus of $1.86.
Guidance: ICU Medical forecasts FY22 adjusted EBITDA of $350-$370 million, down from a prior range of $450-$500 million, and adjusted EPS of $6.20 - $6.80, compared to $9.00 - $10.50 expected earlier.
Raymond James writes that while legacy ICUI continues to perform well (organic revenue growth was +6% y/y in 2Q), inflationary pressures and sluggish Smiths sales continue to weigh on profitability.
The 2022 guidance came in below estimates, as the Smiths acquisition has become a bigger struggle.
The analyst believes that the commentary around recent trends was encouraging, and the implied 4Q guidance gives some hope that '23 should be better.
The analyst has lowered the price target from $208 to $190 with an Outperform rating unchanged.
Price Action: ICUI shares are down 10.7% at $168.07 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.